The Evolution of Cytochrome P450 Enzymes as Biocatalysts in Drug Discovery and Development

2013 ◽  
Vol 13 (18) ◽  
pp. 2254-2280 ◽  
Author(s):  
Elizabeth Gillam ◽  
Martin Hayes
Bioanalysis ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 1355-1378
Author(s):  
Siva Nageswara Rao Gajula ◽  
Megha Sajakumar Pillai ◽  
Gananadhamu Samanthula ◽  
Rajesh Sonti

Assessment of drug candidate's potential to inhibit cytochrome P450 (CYP) enzymes remains crucial in pharmaceutical drug discovery and development. Both direct and time-dependent inhibition of drug metabolizing CYP enzymes by the concomitant administered drug is the leading cause of drug–drug interactions (DDIs), resulting in the increased toxicity of the victim drug. In this context, pharmaceutical companies have grown increasingly diligent in limiting CYP inhibition liabilities of drug candidates in the early stages and examining risk assessments throughout the drug development process. This review discusses different strategies and decision-making processes for assessing the drug–drug interaction risks by enzyme inhibition and lays particular emphasis on in vitro study designs and interpretation of CYP inhibition data in a stage-appropriate context.


1999 ◽  
Vol 20 (11) ◽  
pp. 432-438 ◽  
Author(s):  
Harry V Gelboin ◽  
Kristopher W Krausz ◽  
Frank J Gonzalez ◽  
Tian J Yang

Sign in / Sign up

Export Citation Format

Share Document